Elaskalani et al. (2017) evidenced that platelet-derived ADP and ATP promote pancreatic cancer cell survival and gemcitabine resistance. Ticagrelor, an inhibitor of ADP-P2Y12 axis, enhances chemotherapeutic efficacy in pancreatic cancer cells by targeting the Novel P2Y12-AKT pathway (Elaskalani et al., 2020). Here, AKT1 is linked to familial pancreatic carcinoma.